Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06246370
Other study ID # GO 23/616
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 20, 2024
Est. completion date September 6, 2025

Study information

Verified date January 2024
Source Hacettepe University
Contact AYNUR DEMIREL, PhD
Phone +9053123051576
Email aynur.demirel@hacettepe.edu.tr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study is to investigate cervical region biomechanics, muscle performance and respiratory muscle strength in patients with Chronic Obstructive Pulmonary Disease (COPD) compared to healthy subjects.


Description:

The secondary purposes are to investigate the correlation between cervical region biomechanics and posture, functional exercise capacity, depression &anxiety level,neck disability, cough severity. In accordance with this purposes, 17 patients with COPD who have Global Initiative for Chronic Obstruction Lung Disease (GOLD) stage 1-2-3-4, being clinically stable for 4 weeks and 17 healthy controls will be included ages>40. Tests and questionnaires will be used in order to determine the severity of COPD and to evaluate posture. Photographical analysis in lateral and posterior views will be used for evaluation of cranioservical region static and dynamic biomechanics. To analyze of chest wall, radiographic evaluation will be performed. Goniometry will be used for evaluation dynamic craniocervical kinematic analysis. Cranioservical region muscle strength and endurance tests will be performed. Respiratory muscle strength tests and cough evaluation test will be performed. Neck disability index, cough evaluation test questionnare, beck depression and anxiety questionnares, Nordic Musculoskeletal questionnare will be used. 6 Minute Pegboard and Ring Test, 6 Minute Walk Test will be performed. According to the results to be obtained, relationship between cranioservical region biomechanics and posture will be investigated based on the severity of disease in patients with COPD. It will guide professional working in the field.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 34
Est. completion date September 6, 2025
Est. primary completion date September 6, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: - • Being diagnosed with stage 1-2-3-4 according to the Classification of Airflow Limitation in COPD (GOLD) system, - Being >40 years old, - Being cognitively competent to understand and answer evaluation questions. - Being clinically stable for the last 4 weeks, - Being under control of accompanying comorbid conditions (such as hypertension, diabetes), - Volunteering to participate in the research. Exclusion Criteria: - • Having been hospitalized due to exacerbation in the last 3 months, - Having a musculoskeletal, neurological, rheumatological or oncological disease that affects the craniocervical & cervicothoracic joints and/or may prevent evaluation, - Having undergone any surgical intervention on the craniocervicofacial region and spine in the last six months, - Having lung malignancy, neoplasm, adenocarcinoma, - Being a lung cancer patient or having received cancer treatment (head and neck lung radiotherapy), having undergone pneumonectemia, lobectomy or resection surgery, - Being treated for anxiety and depression, - Having scoliosis, - Having a congenital anomaly of the craniocervicofacial region. - Having 3 out of 4 findings according to the diagnostic criteria for cervical radiculopathy, - Having thoracic outlet syndrome (TOS)

Study Design


Locations

Country Name City State
Turkey Hacettepe University, Health Sciences Faculty Ankara

Sponsors (1)

Lead Sponsor Collaborator
Hacettepe University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of sagittal cobb angle Cobb anle will measure from X-ray imagination between T2- T12 level. day 1
Primary Cranial rotation angle Tragus- eye horizontal angle will measure from lateral cervical photographs. day 1
Primary evaluation of cervical region biomechanic (dynamic) Investigation of the cervical region range of motions of cervical flexion, cervical extension, cervical lateral flexion, and cervical rotation range of motion. day 1
Primary cervical inclination angle tragus eye and C7 level horizontal angle will measure from lateral cervical photographs. day 1
Primary cervical lateral flexion angle the angle between pogonion-tragus and C7 level will measure from lateral cervical photographs. day 1
Primary Shoulder elevation/depression angle the angle between acromion- C7 level and horizontal line will measure from lateral cervical photographs. day 1
Primary chest wall analysis the distance between 3rd, 7th and 9th ribs and horizontal line will measure from X-Ray day 1
Primary rib angle Sternum and 4th,5th, 6th rib will mark and the angle between these and maximum anteroposteror dimention of the thorax will measure from X-Ray. day 1
Primary diaphragma height the distance between T1- and L2 level will measure from X-Ray. day 1
Secondary postural analysis investigation of posture by photographic analysis in patients with COPD upward rotation/ anterior tilt/internal rotation of scapula, scapular elevation, and scapular abduction evaluations will measure from photographic analysis. day 1
Secondary respiratory muscle strength respiratory muscle strength by mouth pressure device, mean inspiratory pressure and mean expiratory pressure will be tested. day 1
Secondary cervical region muscle strength and endurance investigation of cervical region muscle strength and endurance with stabilizer biofeedback pressure method day 1
Secondary airway flow limitation severity of disease by Global Initiative for Chronic Obstructive Pulmonary Disease scale, GOLD 1: FEV1 (predicted%) =%80 GOLD 2: %50 = FEV1 (predicted% ) < %79 GOLD 3: %30 = FEV1 (predicted%) < %49 GOLD 4 : FEV1 (predicted%) < %30 day 1
Secondary management of cough cough severity will be tested by the Cough evaluation Test.(1-5 scaling of items, 5-25 score range) The minimal important difference was 2. day 1
Secondary Upper Extremity Functional Capacity evaluation of upper extremity functional capacity with 6-minute pegboard ring test day 1
Secondary functional exercise capacity functional exercise capacity by 6 minute walking test. day 1
Secondary anxiety level investigation of anxiety level with the Beck Anxiety Questionnaire (A total score of 0-7 is considered minimal range, 8-15 is mild, 16-25 is moderate, and 26-63 is severe) day 1
Secondary general musculoskeletal pain level general musculoskeletal pain level is evaluated by Nordic Musculoskeletal Questionnare, cut off point is 'one yes answer' day 1
Secondary evaluation of cervical radiculopathy Spurling test
cervical distraction test
cervical rotation test (if + spurling and cervical distraction test side is same with this test and is lower than 60 degree)
upper extremity stretching test
If there are 3 positive answer to 4 tests, cervical radiculopathy existence will be detected.
day 1
Secondary investigation of neck disability severity evaluation of neck disability level by neck disability index,10-point change should be used as the minimum clinically important difference for patients with upper extremity referred sypmtoms day 1
Secondary investigation of the disease severity evaluation of the disease severity with chronic obstructive pulmonary disease severity with Chronic Respiratory Questionnaire MCID( minimal clinically important difference) = a change of 0.5 per item A change in the score of 0.5 on the 7 point scale reflects a clinically significant small change
A change of 1.0 reflects a moderate change
A difference of 1.5 represents a large change
day 1
Secondary investigation of the Pulmonary Function evaluation of pulmonary functions with Lung function test FEV %,FEV1 %, FVC %, FEV1/FVC % , FEF 25-75%, PEF % day 1
Secondary cough sufficiency in patients with COPD evaluation of cough sufficiency with peak expiratory flow meter device, A peak expiratory flow of < 80% predicted was the best cut-off to detect airflow limitation. day 1
Secondary depression level investigation of depression level with Beck Depression Inventory (cut off point is 17 point) Conventional cutoffs are 0-9 for normal range, 10-18 for mild to moderate depression, 19-29 for moderate to severe depression, and 30-63 for severe depression. day 1
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy